Yüklüyor......
Abciximab-induced delayed profound thrombocytopaenia
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary inte...
Kaydedildi:
| Yayımlandı: | BMJ Case Rep |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5534833/ https://ncbi.nlm.nih.gov/pubmed/28576909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-219379 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|